department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

ERTUGLIFLOZIN · pharmadog

pharmadog
drugs
ERTUGLIFLOZIN

drug

patient view →

ERTUGLIFLOZIN

Marketedupdated 2mo ago

by $MRK Merck & Co., Inc.

Approved

community read0 votes

indications

investigational

Type 2 Diabetes

all catalysts(4)

approval · 4

News(0)

no news has mentioned this drug yet

brand

ERTUGLIFLOZIN

generic

ERTUGLIFLOZIN

indication

Type 2 Diabetes

phase

marketed

ERTUGLIFLOZIN — FDA approval

ERTUGLIFLOZIN — FDA approval

ERTUGLIFLOZIN — FDA approval

ERTUGLIFLOZIN — FDA approval

Data sources

openFDA · ClinicalTrials.gov

last refreshed 53m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Patent cliff

source: FDA Orange Book

first barrier falls

Jul 13, 2030

~4.0 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (2)

Jul 13, 2030compositionUS 80805804.0y
Jul 13, 2030compositionUS 80805804.0y

🐶 often sniffed alongside

top 3

tagApproval8 co-mentions · 4 sources
companyAurobindo Pharma Ltd4 co-mentions · 4 sources
tagSmall Molecule4 co-mentions · 4 sources

Trials studying ERTUGLIFLOZIN

phase4DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Studycompletedn=41
phase1Bioequivalence Study of Test Product (T) of Ertugliflozin/Metformin 7.5 mg/ 1000 mg Film Coated Tablets and Reference Product (R) of Segluromet 7.5 mg/ 1000 mg Film Coated Tablets in Healthy, Adult, Human Subjects Under Fed Condition.completedn=36
phase3Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)completedn=166
phase2Ertugliflozin in Chronic Heart Failurerecruitingn=60
phase2ERtugliflozin triAl in DIabetes With Preserved or Reduced ejeCtion FrAcTion mEchanistic Evaluation in Heart Failurecompletedn=34
phase4Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLDrecruitingn=164
phase3Ertugliflozin for Functional Mitral Regurgitationcompletedn=128
EP1Ertugliflozin: Cardioprotective Effects on Epicardial Fatcompletedn=61

more trials →